Identification of Early Biochemical Recurrence Predictors in High-Risk Prostate Cancer Patients Treated with Carbon-Ion Radiotherapy and Androgen Deprivation Therapy

The aim of this retrospective study was to identify clinical predictors early biochemical recurrence (BCR) in patients with high-risk prostate cancer (PCa) treated carbon-ion radiotherapy (CIRT) and androgen deprivation therapy (ADT). A total 670 PCa CIRT ADT were included the study. Early BCR defined as occurring during adjuvant after or within 2 years completion ADT. Univariate multivariate analyses performed BCR. Patients also classified according Systemic Therapy Advancing Metastatic Prostate (STAMPEDE) classification. observed 5.4% patients. Multivariate analysis identified T3b stage ≥75% positive biopsy cores STAMPEDE classification significantly associated based on univariate analysis. These can help clinicians who are at risk In future, combination abiraterone may be an option for BCR, results